NYSE - Nasdaq Real Time Price USD

Johnson & Johnson (JNJ)

Compare
159.66 -0.84 (-0.52%)
As of 13:03 GMT-4. Market open.
Loading Chart for JNJ
DELL
  • Previous close 160.50
  • Open 159.63
  • Bid 159.46 x 1200
  • Ask 159.48 x 800
  • Day's range 158.77 - 159.96
  • 52-week range 143.13 - 168.85
  • Volume 1,781,323
  • Avg. Volume 6,599,684
  • Market cap (intra-day) 384.34B
  • Beta (5Y monthly) 0.52
  • PE ratio (TTM) 24.15
  • EPS (TTM) 6.61
  • Earnings date 15 Oct 2024
  • Forward dividend & yield 4.96 (3.09%)
  • Ex-dividend date 27 Aug 2024
  • 1y target est 172.31

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

www.jnj.com

131,900

Full-time employees

31 December

Fiscal year ends

Healthcare

Sector

Drug Manufacturers - General

Industry

Recent news: JNJ

View more

Performance overview: JNJ

Trailing total returns as of 04/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD return

JNJ
4.25%
S&P 500
20.12%

1-year return

JNJ
6.03%
S&P 500
35.47%

3-year return

JNJ
8.38%
S&P 500
31.50%

5-year return

JNJ
39.66%
S&P 500
96.85%

Compare to: JNJ

Select to analyse similar companies using key performance metrics; select up to four stocks.

Statistics: JNJ

View more

Valuation measures

As of 03/10/2024
  • Market cap

    386.36B

  • Enterprise value

    402.38B

  • Trailing P/E

    24.28

  • Forward P/E

    14.77

  • PEG ratio (5-yr expected)

    0.94

  • Price/sales (ttm)

    4.56

  • Price/book (mrq)

    5.40

  • Enterprise value/revenue

    4.65

  • Enterprise value/EBITDA

    14.61

Financial highlights

Profitability and income statement

  • Profit margin

    43.91%

  • Return on assets (ttm)

    8.10%

  • Return on equity (ttm)

    22.15%

  • Revenue (ttm)

    86.58B

  • Net income avi to common (ttm)

    16.38B

  • Diluted EPS (ttm)

    6.61

Balance sheet and cash flow

  • Total cash (mrq)

    25.48B

  • Total debt/equity (mrq)

    58.00%

  • Levered free cash flow (ttm)

    19.14B

Research analysis: JNJ

View more

Earnings per share

Consensus EPS
 

Revenue vs. Earnings

Revenue 22.45B
Earnings 4.69B
 

Analyst recommendations

  • Strong buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analysts' price targets

150.00
172.31 Average
159.66 Current
215.00 High
 

People also watch